Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Nat Cancer. 2021 Feb 15;2:357–365. doi: 10.1038/s43018-021-00172-1

Table 3.

Percentage of positive cases by selected tumor types. Genes in which P/LP variants were detected are listed by disease type. Note that some patients had multiple P/LP variants, hence some tumor types have more genes with P/LP variants listed than positive cases.

Tumor type Total cases Positive cases Genes with P/LP variants
Astrocytoma 27 5 (19%) BRCA2, SDHD, FANCC, CHEK2, RECQL4
Desmoplastic Small Round Cell Tumor 16 1 (6%) PALB2
Diffuse Intrinsic Pontine Glioma 7 0
Ependymoma 14 3 (21%) NF1, NF2, FANCA
Ewing sarcoma 31 5 (16%) MLH1, CHEK2, TMEM127, MITF, APC I1307K (2)
Ganglioglioma 7 1 (14%) SUFU
Gastrointestinal stromal tumor 4 3 (75%) SDHA, SDHB, SDHC
Germ cell tumor 17 2 (12%) PMS2, APC I1307K
Glioblastoma 13 3 (23%) PMS2 (homozygous), NF1, CHEK2, MUTYH
Hepatoblastoma 4 1 (25%) PMS2
Hepatocellular carcinoma 11 1 (9%) MUTYH
Malignant Peripheral Nerve Sheath Tumor 7 7 (100%) NF1 (6), MSH2
Medulloblastoma 14 3 (21%) TP53, CHEK2, RECQL4
Meningioma 4 2 (50%) NF2, RB1
Neuroblastoma 182 28 (15%) PHOX2B (3), ALK, TP53, SDHA,
BRCA1, BRCA2, ATM, PTEN, MITF (2), CHEK2 (4), FANCA (2), MUTYH (4), RECQL4 (2), MSH3, ERCC3, APC I1307K (2)
Osteosarcoma 74 7 (9%) RB1 (3), TP53, RAD51D, CDKN2A, MUTYH
Retinoblastoma 70 34 (49%) RB1 (31), ERCC3, MITF, CHEK2, MUTYH (2), MSH3, NTHL1
Rhabdomyosarcoma 45 9 (20%) DICER1, TP53, MSH6, VHL, NBN, APC I1307K (2), FANCC
Wilms tumor 25 2 (8%) APC I1307K, MUTYH